SEC Filing Summary: Aadi Bioscience, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Aadi Bioscience, Inc. on May 10, 2023. The report announces the financial results for the quarter ended March 31, 2023. The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol "AADI". Scott Giacobello serves as Interim Chief Executive Officer, President, and Chief Financial Officer.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors in the main text. It directs readers to the press release for the full announcement of results. The document includes a standard disclaimer stating that the information furnished in Item 2.02 and Item 9.01 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended March 31, 2023, by reviewing the attached press release (Exhibit 99.1).
- Confirm the company's current cash position and burn rate, as these are not listed in the 8-K summary text.
- Note the leadership structure with Scott Giacobello serving in an interim capacity as CEO and CFO.
- Check for any forward-looking statements or updated clinical trial timelines in the referenced press release.